Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
Delayed Nasdaq  -  04:00 2022-11-30 pm EST
11.10 USD   +2.78%
11/29Alx Oncology Holdings Inc : Change in Directors or Principal Officers (form 8-K)
AQ
11/29Alx Oncology : Corporate Presentation
PU
11/29ALX Oncology Appoints Scott Garland to its Board of Directors
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference

09/21/2022 | 04:01pm EST

SOUTH SAN FRANCISCO, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will participate in a panel and investor meetings at the Cantor Oncology, Hematology & HemeOnc Conference on Wednesday, September 28 in New York.

Format: Moderated panel with analysts, Li Watsek & Brandon Folkes
Panel: “Building Combinations: What are the Novel Ideas?”
Date: Wednesday, September 28
Time: 10:40 AM Eastern Time
Location: New York, NY

Dr. Pons and Mr. Peter Garcia, CFO of ALX Oncology, will be hosting one-on-one meetings during the conference. To schedule a one-on-one meeting with the ALX Oncology management team, please contact your Cantor conference representative.

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of evorpacept for the treatment of multiple solid tumor indications and hematologic malignancies.


Investor Contact:

Peter Garcia
Chief Financial Officer, ALX Oncology
(650) 466-7125 Ext. 113
peter@alxoncology.com

Argot Partners
(212) 600-1902
alxoncology@argotpartners.com

Media Contact:

Karen Sharma
MacDougall
(781) 235-3060
alx@macbiocom.com

Primary Logo

Source: ALX Oncology

2022 GlobeNewswire, Inc., source Press Releases

All news about ALX ONCOLOGY HOLDINGS INC.
11/29Alx Oncology Holdings Inc : Change in Directors or Principal Officers (form 8-K)
AQ
11/29Alx Oncology : Corporate Presentation
PU
11/29ALX Oncology Appoints Scott Garland to its Board of Directors
GL
11/29ALX Oncology Appoints Scott Garland to its Board of Directors
GL
11/29ALX Oncology Holdings Inc. Appoints Scott Garland to Its Board of Directors
CI
11/09Transcript : ALX Oncology Holdings Inc. Presents at Credit Suisse 31st Annual..
CI
11/09HC Wainwright Lowers Price Target on ALX Oncology Holdings to $65 From $80, Maintains B..
MT
11/08ALX ONCOLOGY HOLDINGS INC Management's Discussion and Analysis of Financial Condition ..
AQ
11/08ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Develop..
GL
11/08ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Develop..
AQ
More news
Analyst Recommendations on ALX ONCOLOGY HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -131 M - -
Net cash 2022 255 M - -
P/E ratio 2022 -3,49x
Yield 2022 -
Capitalization 452 M 452 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 55
Free-Float 73,6%
Chart ALX ONCOLOGY HOLDINGS INC.
Duration : Period :
ALX Oncology Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALX ONCOLOGY HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 11,10 $
Average target price 35,00 $
Spread / Average Target 215%
EPS Revisions
Managers and Directors
Jaume Pons President, Chief Executive Officer & Director
Peter S. GarcÝa Chief Financial Officer
Corey S. Goodman Executive Chairman
Sophia Randolph Director & Chief Medical Officer
Michael Chang Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ALX ONCOLOGY HOLDINGS INC.-48.35%452
VERTEX PHARMACEUTICALS44.08%81 199
REGENERON PHARMACEUTICALS, INC.16.56%78 615
BIONTECH SE-35.21%39 760
WUXI APPTEC CO., LTD.-34.22%31 776
GENMAB A/S20.91%28 866